Skip to main content

Advertisement

SpringerLink
Log in

Description of paclitaxel resistance-associated genes in ovarian and breast cancer cell lines

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

To identify genes involved in the paclitaxel resistance phenotype.

Methods

High-density Affymetrix HG-U95Av2 microarrays were used to quantify gene expression in the resulting cell lines, SKOV-3TR, OVCAR8TR and MCF-7TR, and their drug-sensitive parental lines, SKOV-3, OVCAR8 and MCF-7.

Results

Three paclitaxel-resistant human ovarian and breast cancer cell lines were established. We identified 790 (SKOV-3TR), 689 (OVCAR8TR) and 964 (MCF-7TR) transcripts that were more than twofold overexpressed relative to their expression in the corresponding parental cell line. A comparison of these transcripts identified eight genes that were significantly overexpressed in all three drug-resistant daughter cell lines. These genes included MDR1, a gene often implicated in both in vitro and in vivo resistance to multiple chemotherapeutics, including paclitaxel. The remaining seven genes have not been previously associated with resistance to paclitaxel in human cancer. Furthermore, we identified 815 (SKOV-3TR), 430 (OVCAR8TR) and 332 (MCF-7TR) transcripts that were more than twofold decreased relative to their expression in the corresponding parental cell line. Comparison of these transcripts identified three genes that were significantly underexpressed in all three drug-resistant cell lines, none of which have been previously associated with paclitaxel resistance.

Conclusions

Our results confirm that the paclitaxel resistance phenotype is associated with a large number of transcriptional changes. In addition, acquired paclitaxel resistance was associated with distinct transcriptional changes in each of the cell lines studied, suggesting that paclitaxel resistance is a complex phenotype that can arise through multiple mechanisms.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. McGuire WP, Blessing JA, Moore D, Lentz SS, Photopulos G (1996) Paclitaxel has moderate activity in squamous cervix cancer. A Gynecologic Oncology Group study. J Clin Oncol 14:792

    CAS  PubMed  Google Scholar 

  2. Loe DW, Deeley RG, Cole SP (1996) Biology of the multidrug resistance-associated protein, MRP. Eur J Cancer 32A:945

    Article  CAS  PubMed  Google Scholar 

  3. Volm M (1998) Multidrug resistance and its reversal. Anticancer Res 18:2905

    CAS  PubMed  Google Scholar 

  4. Ferreira CG, Tolis C, Giaccone G (1999) p53 and chemosensitivity. Ann Oncol 10:1011

    Article  CAS  PubMed  Google Scholar 

  5. Lamendola DE, Duan Z, Yusuf RZ, Seiden MV (2003) Molecular description of evolving paclitaxel resistance in the SKOV-3 human ovarian carcinoma cell line. Cancer Res 63:2200

    CAS  PubMed  Google Scholar 

  6. Watts GS, Futscher BW, Isett R, Gleason-Guzman M, Kunkel MW, Salmon SE (2001) cDNA microarray analysis of multidrug resistance: doxorubicin selection produces multiple defects in apoptosis signaling pathways. J Pharmacol Exp Ther 299:434

    CAS  PubMed  Google Scholar 

  7. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M (1996) Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334:1

    Article  CAS  PubMed  Google Scholar 

  8. Brockstein B, Haraf DJ, Stenson K, Fasanmade A, Stupp R, Glisson B, Lippman SM, Ratain MJ, Sulzen L, Klepsch A, Weichselbaum RR, Vokes EE (1998) Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, and hydroxyurea with granulocyte colony-stimulating factor support for patients with poor-prognosis cancer of the head and neck. J Clin Oncol 16:735

    CAS  PubMed  Google Scholar 

  9. Dumontet C, Duran GE, Steger KA, Beketic-Oreskovic L, Sikic BI (1996) Resistance mechanisms in human sarcoma mutants derived by single-step exposure to paclitaxel (Taxol). Cancer Res 56:1091

    CAS  PubMed  Google Scholar 

  10. Giannakakou P, Sackett DL, Kang YK, Zhan Z, Buters JT, Fojo T, Poruchynsky MS (1997) Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem 272:17118

    Article  CAS  PubMed  Google Scholar 

  11. Yusuf RZ, Duan Z, Lamendola DE, Penson RT, Seiden MV (2003) Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation. Curr Cancer Drug Targets 3:1

    CAS  PubMed  Google Scholar 

  12. Duan Z, Feller AJ, Penson RT, Chabner BA, Seiden MV (1999) Discovery of differentially expressed genes associated with paclitaxel resistance using cDNA array technology: analysis of interleukin (IL) 6, IL-8, and monocyte chemotactic protein 1 in the paclitaxel-resistant phenotype. Clin Cancer Res 5:3445

    CAS  PubMed  Google Scholar 

  13. Duan Z, Feller AJ, Toh HC, Makastorsis T, Seiden MV (1999) TRAG-3, a novel gene, isolated from a taxol-resistant ovarian carcinoma cell line. Gene 229:75

    Article  CAS  PubMed  Google Scholar 

  14. Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB (1987) Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of radiosensitivity. Cancer Res 47:943

    CAS  PubMed  Google Scholar 

  15. Duan Z, Lamendola DE, Penson RT, Kronish KM, Seiden MV (2002) Overexpression of IL-6 but not IL-8 increases paclitaxel resistance of U-2OS human osteosarcoma cells. Cytokine 17:234

    Article  CAS  PubMed  Google Scholar 

  16. Duan Z, Lamendola DE, Yusuf RZ, Penson RT, Preffer FI, Seiden MV (2002) Overexpression of human phosphoglycerate kinase 1 (PGK1) induces a multidrug resistance phenotype. Anticancer Res 22:1933

    CAS  PubMed  Google Scholar 

  17. Duan Z, Duan Y, Lamendola DE, Yusuf RZ, Naeem R, Penson RT, Seiden MV (2003) Overexpression of MAGE/GAGE genes in paclitaxel/doxorubicin-resistant human cancer cell lines. Clin Cancer Res 9:2778

    CAS  PubMed  Google Scholar 

  18. Dolci ED, Abramson R, Xuan Y, Siegfried J, Yuenger KA, Yassa DS, Tritton TR (1993) Anomalous expression of P-glycoprotein in highly drug-resistant human KB cells. Int J Cancer 54:302

    CAS  PubMed  Google Scholar 

  19. Baird RD, Kaye SB (2003) Drug resistance reversal—are we getting closer? Eur J Cancer 39:2450

    Article  CAS  PubMed  Google Scholar 

  20. Penson R, Skates SJ, Glyptis T, Fuller AF, Goodman A, Seiden MV (2004) Expression of multidrug resistance-1 protein inversely correlates with paclitaxel response and survival in ovarian cancer patients: a study in serial samples. Gynecol Oncol 93:98

    Article  CAS  PubMed  Google Scholar 

  21. Seiden MV, Swenerton KD, Matulonis U, Campos S, Rose P, Batist G, Ette E, Garg V, Fuller A, Harding MW, Charpentier D (2002) A phase II study of the MDR inhibitor biricodar (INCEL, VX-710) and paclitaxel in women with advanced ovarian cancer refractory to paclitaxel therapy. Gynecol Oncol 86:302

    Article  CAS  PubMed  Google Scholar 

  22. Smith AJ, van Helvoort A, van Meer G, Szabo K, Welker E, Szakacs G, Varadi A, Sarkadi B, Borst P (2000) MDR3 P-glycoprotein, a phosphatidylcholine translocase, transports several cytotoxic drugs and directly interacts with drugs as judged by interference with nucleotide trapping. J Biol Chem 275:23530

    Article  CAS  PubMed  Google Scholar 

  23. Arai Y, Masuda M, Sugawara I, Arai T, Motoji T, Tsuruo T, Oshimi K, Mizoguchi H (1997) Expression of the MDR1 and MDR3 gene products in acute and chronic leukemias. Leuk Res 21:313

    Article  CAS  PubMed  Google Scholar 

  24. Shibata K, Kikkawa F, Nawa A, Suganuma N, Hamaguchi M (1997) Fibronectin secretion from human peritoneal tissue induces Mr 92,000 type IV collagenase expression and invasion in ovarian cancer cell lines. Cancer Res 57:5416

    CAS  PubMed  Google Scholar 

  25. Vargas-Roig LM, Fanelli MA, Lopez LA, Gago FE, Tello O, Aznar JC, Ciocca DR (1997) Heat shock proteins and cell proliferation in human breast cancer biopsy samples. Cancer Detect Prev 21:441

    CAS  PubMed  Google Scholar 

  26. Nylandsted J, Rohde M, Brand K, Bastholm L, Elling F, Jaattela M (2000) Selective depletion of heat shock protein 70 (Hsp70) activates a tumor-specific death program that is independent of caspases and bypasses Bcl-2. Proc Natl Acad Sci U S A 97:7871

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgement

This work was supported by NIH Grant CA 89150 (to M.V. Seiden).

Author information

Authors and Affiliations

  1. Department of Hematology/Oncology, Massachusetts General Hospital, Boston, MA, 02114, USA

    Zhenfeng Duan, Diana E. Lamendola, Yifei Duan, Rushdia Z. Yusuf & Michael V. Seiden

Authors
  1. Zhenfeng Duan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Diana E. Lamendola
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yifei Duan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Rushdia Z. Yusuf
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Michael V. Seiden
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Zhenfeng Duan.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Duan, Z., Lamendola, D.E., Duan, Y. et al. Description of paclitaxel resistance-associated genes in ovarian and breast cancer cell lines. Cancer Chemother Pharmacol 55, 277–285 (2005). https://doi.org/10.1007/s00280-004-0878-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-004-0878-y

Keywords

Search

Navigation